Key Spec Table
|Species Reactivity||Key Applications||Host||Format||Antibody Type|
|H||FC, IHC, IP, WB||M||Purified||Monoclonal Antibody|
|Application||Detect ZAP-70 using this Anti-ZAP-70 Antibody, clone 2F3.2 validated for use in FC, IH, IP & WB.|
|Application Notes||For testing in IHC, please see the following link (PDF): http://www.propathlab.com/pdf/focus_dec_2003.pdf|
|Safety Information according to GHS|
|Storage and Shipping Information|
|Storage Conditions||2 years at -20°C|
|Material Size||1 mg|
|Anti-ZAP-70 (human), clone 2F3.2 (mouse monoclonal IgG2a)||2891854|
|Anti-ZAP-70 (human), clone 2F3.2 - JBC1356674||JBC1356674|
|Anti-ZAP-70 (human), clone 2F3.2 -2595016||2595016|
|Anti-ZAP-70, clone 2F3.2 - 24680||24680|
|Anti-ZAP-70, clone 2F3.2 - 26514A||26514A|
|Reference overview||Application||Pub Med ID|
|TCR signaling: another Abl-bodied kinase joins the cascade.|
Wange, Ronald L
Curr. Biol., 14: R562-4 (2004) 2004
Protein tyrosine kinases have long been recognized as the most proximal actors in T-cell antigen receptor (TCR) signaling. Three non-receptor tyrosine kinase families (Src, ZAP-70 and Tec) are known to be critical, but a new study now shows that room needs to be made in this pathway for yet another protein tyrosine kinase family - Abl/Arg.
|ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.|
Crespo, Marta, et al.
N. Engl. J. Med., 348: 1764-75 (2003) 2003
BACKGROUND: The mutational status of immunoglobulin heavy-chain variable-region (IgVH) genes in the leukemic cells of chronic lymphocytic leukemia (CLL) is an important prognostic factor in the disease. We investigated whether the expression of ZAP-70 by CLL cells correlated with the IgVH mutational status, disease progression, and survival. METHODS: The expression of ZAP-70 was analyzed in T-cell and B-cell lines and in peripheral-blood samples from 56 patients with CLL with the use of flow cytometry, Western blotting, and immunohistochemistry. The results were correlated with the IgVH mutational status and clinical outcome. RESULTS: ZAP-70 was detected by flow-cytometric analysis in cells of T-cell lineage and in leukemic cells from 32 of 56 patients with CLL. In all patients in whom at least 20 percent of the leukemic cells were positive for ZAP-70, IgVH was unmutated, whereas IgVH mutations were found in 21 of 24 patients in whom less than 20 percent of the leukemic cells were positive for ZAP-70 (P<0.001). Concordant results were obtained when ZAP-70 expression was assessed by immunohistochemistry or Western blotting. The level of ZAP-70 expression did not change over time (median, 37 months) in sequential samples from 30 patients with CLL. Patients with Binet stage A CLL who had at least 20 percent ZAP-70-positive leukemic cells had more rapid progression and poorer survival than those with less than 20 percent ZAP-70-positive cells. CONCLUSIONS: Among patients with CLL, expression of ZAP-70, as detected by flow-cytometric analysis, correlated with IgVH mutational status, disease progression, and survival.
|The Syk family of protein tyrosine kinases in T-cell activation and development.|
Chu, D H, et al.
Immunol. Rev., 165: 167-80 (1998) 1998